Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Teikyo University Institute of Medical Mycology, 359 Otsuka, Hachioji, Tokyo, 192-0395, Japan.
Nat Commun. 2019 Jul 5;10(1):2992. doi: 10.1038/s41467-019-10754-4.
Lysocin E, a 37-membered natural depsipeptide, induces rapid bacteriolysis in methicillin-resistant Staphylococcus aureus via a unique menaquinone-dependent mechanism, presenting a promising therapeutic lead. Despite the great medical importance, exploring the potential utility of its derivatives as new platform structures for antibiotic development has remained a significant challenge. Here, we report a high-throughput strategy that enabled the preparation of thousands of analogues of lysocin E and large-scale structure-activity relationship analyses. We integrate 26-step total synthesis of 2401 cyclic peptides, tandem mass spectrometry-sequencing, and two microscale activity assays to identify 23 candidate compounds. Re-synthesis of these candidates shows that 11 of them (A1-A11) exhibit antimicrobial activity superior or comparable to that of lysocin E, and that lysocin E and A1-A11 share L-Leu-6 and L-Ile-11. Therefore, the present strategy allows us to efficiently decipher biologically crucial residues and identify potentially useful agents for the treatment of infectious diseases.
赖氨酸 E,一种由 37 个氨基酸组成的天然环缩肽,通过独特的依赖甲萘醌的机制诱导耐甲氧西林金黄色葡萄球菌的快速溶菌,具有很大的治疗潜力。尽管具有重要的医学意义,但探索其衍生物作为新的抗生素开发平台结构的潜力仍然是一个重大挑战。在这里,我们报告了一种高通量策略,该策略能够制备数千种赖氨酸 E 的类似物,并进行大规模的结构-活性关系分析。我们整合了 26 步全合成的 2401 种环状肽、串联质谱测序和两种微量活性测定,以鉴定出 23 种候选化合物。这些候选化合物的重新合成表明,其中 11 种(A1-A11)具有优于或相当于赖氨酸 E 的抗菌活性,并且赖氨酸 E 和 A1-A11 共享 L-Leu-6 和 L-Ile-11。因此,本策略能够有效地揭示生物关键残基,并鉴定出可能用于治疗传染病的有用药物。